Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants

• Published in: Vaccine Vol. 33; no. 16; pp. 1897 - 1900
• Main Authors: Scheifele, David W., Ferguson, Murdo, Predy, Gerald, Dawar, Meena, Assudani, Deepak, Kuriyakose, Sherine, Van Der Meeren, Olivier, Han, Htay-Htay
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 15.04.2015; Elsevier Limited
• Subjects: Aboriginal; Allergy and Immunology; Antibodies, Bacterial - blood; Antibodies, Bacterial - immunology; Birth weight; Canada - epidemiology; Canada - ethnology; Combination vaccine; Communicable Disease Control - methods; Communicable Disease Control - statistics & numerical data; Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage; Diphtheria-Tetanus-Pertussis Vaccine - adverse effects; Diphtheria-Tetanus-Pertussis Vaccine - immunology; Female; geometry; Haemophilus influenzae; Haemophilus influenzae b; Haemophilus Vaccines - administration & dosage; Haemophilus Vaccines - adverse effects; Haemophilus Vaccines - immunology; Hepatitis B; Hepatitis B Antibodies - blood; Hepatitis B Antibodies - immunology; Hepatitis B Vaccines - administration & dosage; Hepatitis B Vaccines - adverse effects; Hepatitis B Vaccines - immunology; Hepatitis B virus; Humans; immune response; Immunization; Immunogenicity; Infant; Infants; Male; Native peoples; Public Health Surveillance; Safety; Vaccination; Vaccines; Canada; Combination vaccine; Aboriginal; Haemophilus influenzae b; Safety; Immunogenicity; Hepatitis B
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2015.02.015

•These are the first available data on immune responses of Canadian Aboriginal infants to routine vaccines.•Responses of Aboriginal and non-Aboriginal infants were compared after 3 doses of a hexavalent combination vaccine.•Responses to H. influenzae b and hepatitis B components were at least as high in Aboriginal as in non-Aboriginal infants. This study compared immune responses of healthy Aboriginal and non-Aboriginal infants to Haemophilus influenzae type b (Hib) and hepatitis B virus (HBV) components of a DTaP-HBV-IPV/Hib combination vaccine, 1 month after completing dosing at 2, 4 and 6 months of age. Of 112 infants enrolled in each group, 94 Aboriginal and 107 non-Aboriginal infants qualified for the immunogenicity analysis. Anti-PRP concentrations exceeded the protective minimum (≥0.15μg/ml) in ≥97% of infants in both groups but geometric mean concentrations (GMCs) were higher in Aboriginal infants (6.12μg/ml versus 3.51μg/ml). All subjects were seroprotected (anti-HBs ≥10mIU/mL) against HBV, with groups having similar GMCs (1797.9 versus 1544.4mIU/mL, Aboriginal versus non-Aboriginal, respectively). No safety concerns were identified. We conclude that 3-dose primary vaccination with DTaP-HBV-IPV/Hib combination vaccine elicited immune responses to Hib and HBV components that were at least as high in Aboriginal as in non-Aboriginal Canadian infants. Clinical Trial Registration NCT00753649.